Company Information

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. 

Investor Relations

Crescendo Communications, LLC
David Waldman
5 Penn Plaza
Suite 1953
New York, NY 10001
T: 212-671-1021
ADIL@crescendo-ir.com

Adial Pharma Contact

Adial Pharmaceutical, Inc.
1180 Seminole Trail
Ste 495
Charlottesville, VA 22901
T: 434-422-9800
info@adialpharma.com